Literature DB >> 28450731

Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989-2015.

M van der Meulen1, A G Dinmohamed2,3,4, O Visser5, J K Doorduijn4, J E C Bromberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28450731     DOI： 10.1038/leu.2017.128

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.

Authors:  Antonio Omuro; Olivier Chinot; Luc Taillandier; Hervé Ghesquieres; Carole Soussain; Vincent Delwail; Thierry Lamy; Rémy Gressin; Sylvain Choquet; Pierre Soubeyran; Aymeri Huchet; Alexandra Benouaich-Amiel; Sophie Lebouvier-Sadot; Emmanuel Gyan; Valérie Touitou; Maryline Barrié; Monica Sierra del Rio; Alberto Gonzalez-Aguilar; Caroline Houillier; Daniel Delgadillo; Lucette Lacomblez; Marie Laure Tanguy; Khê Hoang-Xuan
Journal:  Lancet Haematol       Date:  2015-06-03       Impact factor: 18.959

Review 2.  First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.

Authors:  B Kasenda; A J M Ferreri; E Marturano; D Forst; J Bromberg; H Ghesquieres; C Ferlay; J Y Blay; K Hoang-Xuan; E J Pulczynski; A Fosså; Y Okoshi; S Chiba; K Fritsch; A Omuro; B P O'Neill; O Bairey; S Schandelmaier; V Gloy; N Bhatnagar; S Haug; S Rahner; T T Batchelor; G Illerhaus; M Briel
Journal:  Ann Oncol       Date:  2015-02-20       Impact factor: 32.976

3.  Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010.

Authors:  Djamila E Issa; Saskia A M van de Schans; Martine E D Chamuleau; Henrike E Karim-Kos; Marielle Wondergem; Peter C Huijgens; Jan Willem W Coebergh; Sonja Zweegman; Otto Visser
Journal:  Haematologica       Date:  2014-12-15       Impact factor: 9.941

4.  High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.

Authors:  Andrés J M Ferreri; Michele Reni; Marco Foppoli; Maurizio Martelli; Gerasimus A Pangalis; Maurizio Frezzato; Maria Giuseppina Cabras; Alberto Fabbri; Gaetano Corazzelli; Fiorella Ilariucci; Giuseppe Rossi; Riccardo Soffietti; Caterina Stelitano; Daniele Vallisa; Francesco Zaja; Lucía Zoppegno; Gian Marco Aondio; Giuseppe Avvisati; Monica Balzarotti; Alba A Brandes; José Fajardo; Henry Gomez; Attilio Guarini; Graziella Pinotti; Luigi Rigacci; Catrina Uhlmann; Piero Picozzi; Paolo Vezzulli; Maurilio Ponzoni; Emanuele Zucca; Federico Caligaris-Cappio; Franco Cavalli
Journal:  Lancet       Date:  2009-09-18       Impact factor: 79.321

5.  Completeness of cancer registration in Limburg, The Netherlands.

Authors:  L J Schouten; P Höppener; P A van den Brandt; J A Knottnerus; J J Jager
Journal:  Int J Epidemiol       Date:  1993-06       Impact factor: 7.196

6.  Patterns of treatment in older adults with primary central nervous system lymphoma.

Authors:  Katherine S Panageas; Elena B Elkin; Leah Ben-Porat; Lisa M Deangelis; Lauren E Abrey
Journal:  Cancer       Date:  2007-09-15       Impact factor: 6.860

7.  Age, gender, and racial differences in incidence and survival in primary CNS lymphoma.

Authors:  J L Villano; M Koshy; H Shaikh; T A Dolecek; B J McCarthy
Journal:  Br J Cancer       Date:  2011-09-13       Impact factor: 7.640

8.  Population-based Incidence and Survival for Primary Central Nervous System Lymphoma in Korea, 1999-2009.

Authors:  Sang-Hoon Shin; Kyu-Won Jung; Johyun Ha; Seung Hoon Lee; Young-Joo Won; Heon Yoo
Journal:  Cancer Res Treat       Date:  2015-02-12       Impact factor: 4.679

9.  High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study).

Authors:  K Fritsch; B Kasenda; E Schorb; P Hau; J Bloehdorn; R Möhle; S Löw; M Binder; J Atta; U Keller; H-H Wolf; S W Krause; G Heß; R Naumann; S Sasse; C Hirt; M Lamprecht; U Martens; A Morgner; J Panse; N Frickhofen; A Röth; C Hader; M Deckert; H Fricker; G Ihorst; J Finke; G Illerhaus
Journal:  Leukemia       Date:  2016-11-15       Impact factor: 11.528

10.  Trends in primary central nervous system lymphoma incidence and survival in the U.S.

Authors:  Meredith S Shiels; Ruth M Pfeiffer; Caroline Besson; Christina A Clarke; Lindsay M Morton; Leticia Nogueira; Karen Pawlish; Elizabeth L Yanik; Gita Suneja; Eric A Engels
Journal:  Br J Haematol       Date:  2016-03-28       Impact factor: 8.615
View more
  14 in total

1.  Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study.

Authors:  R Velasco; S Mercadal; F Graus; N Vidal; M Alañá; M I Barceló; M J Ibáñez-Juliá; S Bobillo; R Caldú Agud; E García Molina; P Martínez; P Cacabelos; A Muntañola; G García-Catalán; J M Sancho; I Camro; T Lado; M E Erro; L Gómez-Vicente; A Salar; A C Caballero; M Solé-Rodríguez; J Gállego Pérez-Larraya; N Huertas; J Estela; M Barón; N Barbero-Bordallo; M Encuentra; I Dlouhy; J Bruna
Journal:  J Neurooncol       Date:  2020-06-10       Impact factor: 4.130

2.  The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades.

Authors:  Joe S Mendez; Quinn T Ostrom; Haley Gittleman; Carol Kruchko; Lisa M DeAngelis; Jill S Barnholtz-Sloan; Christian Grommes
Journal:  Neuro Oncol       Date:  2018-04-09       Impact factor: 12.300

3.  Outcome and Prognostic Factors of Primary Central Nervous System Lymphoma in Southern Thailand.

Authors:  Thanya Sopittapan; Thara Tunthanathip; Anukoon Kaewborisutsakul
Journal:  Asian J Neurosurg       Date:  2020-08-28

4.  Management and outcome of primary CNS lymphoma in the modern era: An LOC network study.

Authors:  Caroline Houillier; Carole Soussain; Hervé Ghesquières; Pierre Soubeyran; Olivier Chinot; Luc Taillandier; Thierry Lamy; Sylvain Choquet; Guido Ahle; Gandhi Damaj; Philippe Agapé; Cécile Moluçon-Chabrot; Alexandra Amiel; Vincent Delwail; Michel Fabbro; Fabrice Jardin; Adrien Chauchet; Marie-Pierre Moles-Moreau; Franck Morschhauser; Olivier Casasnovas; Rémy Gressin; Luc-Matthieu Fornecker; Julie Abraham; Jean-Pierre Marolleau; Adrian Tempescul; Chantal Campello; Philippe Colin; Jérôme Tamburini; Kamel Laribi; Caroline Serrier; Corinne Haioun; Safia Chebrek; Anna Schmitt; Marie Blonski; Roch Houot; Eileen Boyle; Jacques-Olivier Bay; Lucie Oberic; Emeline Tabouret; Agathe Waultier; Nadine Martin-Duverneuil; Valérie Touitou; Nathalie Cassoux; Aurélie Kas; Karima Mokhtari; Frederic Charlotte; Agusti Alentorn; Loïc Feuvret; Magali Le Garff-Tavernier; Myrto Costopoulos; Bertrand Mathon; Matthieu Peyre; Daniel Delgadillo; Hassen Douzane; Diane Genet; Bachir Aidaoui; Khê Hoang-Xuan; Emmanuel Gyan
Journal:  Neurology       Date:  2020-01-06       Impact factor: 9.910

5.  Changing Incidence and Survival of Primary Central Nervous System Lymphoma in Australia: A 33-Year National Population-Based Study.

Authors:  Alexandra L Farrall; Justine R Smith
Journal:  Cancers (Basel)       Date:  2021-01-22       Impact factor: 6.639

6.  Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (Review).

Authors:  Yanxia Liu; Qingmin Yao; Feng Zhang
Journal:  Int J Oncol       Date:  2021-02-01       Impact factor: 5.650

7.  Clinical features and outcome of patients with primary central nervous system lymphoma admitted to the intensive care unit: a French national expert center experience.

Authors:  Maxens Decavèle; Aliénor Dreyfus; Nicolas Gatulle; Nicolas Weiss; Caroline Houillier; Sophie Demeret; Julien Mayaux; Isabelle Rivals; Martin Dres; Julie Delemazure; Elise Morawiec; Charles-Edouard Luyt; Khe Hoang-Xuan; Sylvain Choquet; Thomas Similowski; Alexandre Demoule
Journal:  J Neurol       Date:  2021-01-16       Impact factor: 4.849

8.  Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial.

Authors:  Matthijs van der Meulen; Linda Dirven; Esther J J Habets; Katerina Bakunina; Marion Smits; Hakim C Achterberg; Tatjana Seute; Gavin Cull; Harry Schouten; Josée M Zijlstra; Dieta Brandsma; Roelien H Enting; Max Beijert; Martin J B Taphoorn; Martin J van den Bent; Samar Issa; Jeanette K Doorduijn; Jacoline E C Bromberg
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 12.300

9.  MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma.

Authors:  Matthijs van der Meulen; Linda Dirven; Katerina Bakunina; Martin J van den Bent; Samar Issa; Jeanette K Doorduijn; Jacoline E C Bromberg
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

10.  Primary therapy and survival in patients aged over 70-years-old with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands.

Authors:  Matthijs van der Meulen; Jacoline E C Bromberg; Marcel Nijland; Otto Visser; Jeanette K Doorduijn; Avinash G Dinmohamed
Journal:  Haematologica       Date:  2021-02-01       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.